Healthcare workers (HCW) were prioritized for vaccination during the 2009 influenza A(H1N1)pdm09 pandemic. We conducted a clinical trial in October 2009 where 237 HCWs were immunized with a AS03-adjuvanted A(H1N1)pdm09 monovalent vaccine. In the current study, we analyzed the homologous and cross-reactive H1N1 humoral responses using prototype vaccine strains dating back to 1977 by the haemagglutinin inhibition (HI), single radial hemolysis SRH), antibody secreting cell (ASC) and memory B cell (MBC) assays. The cellular responses were assessed by interferon-g (IFN-g) ELISPOT and by intracellular staining (ICS) for the Th1 cytokines IFN-g, interleukin-2 (IL-2) and tumor necrosis factor-a (TNF-a). All assays were performed using blood samples obtained prior to (day 0) and 7, 14 and 21 d postpandemic vaccination, except for ASC (day 7) and ICS (days 0 and 21). Vaccination elicited rapid HI, SRH and ASC responses against A(H1N1)pdm09 which cross reacted with seasonal H1N1 strains. MBC responses were detected against the homologous and seasonal H1N1 strains before vaccination and were boosted 2 weeks post-vaccination. An increase in cellular responses as determined by IFN-g ELISPOT and ICS were observed 1-3 weeks after vaccination. Collectively, our data show that the AS03-adjuvanted A(H1N1)pdm09 vaccine induced rapid cellular and humoral responses against the vaccine strain and the response cross-reacted against prototype H1N1 strains dating back to 1977.
Introduction
The novel, swine-origin influenza A(H1N1)pdm09 virus was first detected in April 2009 and it caused the first influenza pandemic of the 21 st century. The A(H1N1)pdm09 virus was antigenically distinct from the prior seasonal influenza A strains and the majority of the population was immunologically na€ ıve to A (H1N1)pdm09 rendering existing influenza vaccines ineffective against this strain.
1-3 New pandemic vaccines were developed against A(H1N1)pdm09 and they induced sero-protective antibody responses 1-2 weeks after administering a single dose in most healthy adults. 4 Since 2009, the A(H1N1)pdm09 virus has circulated and has been included in the seasonal trivalent influenza vaccines (TIV) as the H1N1 strain.
Antibody responses are a key mediator of sero-protective immunity induced by influenza vaccines. 5 At the start of the pandemic, there were no or little antibody titres against the A (H1N1)pdm09 strain, especially in young adults and children resulting in atypically high rates of severe disease. 2, 3 However, people over the age of 60 had higher levels of sero-protective immunity, most likely due to having pre-existing, cross-reactive antibodies from prior exposure to A(H1N1)pdm09-like strains in the distant past. 6 In this regard, infection with A(H1N1) pdm09 has been shown to activate broadly-cross reactive memory B cells that provided protection even in the absence of pre-existing antibody titres. 7 Of interest, recent studies have shown that antibodies specific for the conserved stalk domain of the influenza haemagglutinin were boosted by vaccination and infection with the novel A(H1N1)pdm09 virus and these antibodies have broad cross-reactive neutralizing activity against different group 1 influenza strains. 6, 8, 9 In addition to antibody responses, T cells play a significant role in anti-influenza immunity. A large percentage of T-cell epitopes found in seasonal H1N1 strains in the years preceding the pandemic were conserved in A(H1N1)pdm09, thus were targets of immunological memory. 10 A recent report showed that high frequencies of pre-existing T cells to conserved epitopes on A(H1N1)pdm09 virus were found in people that developed less severe disease, suggesting a key role for cellular immunity in anti-A(H1N1)pdm09 responses. 11 During the 2009 pandemic, HCWs were prioritized for vaccination in order to maintain the integrity of the healthcare system and to minimize virus transfer to vulnerable patients. In October 2009, we conducted a clinical trial in frontline HCWs to evaluate the safety and immunogenicity of a single dose of a A(H1N1) pdm09 vaccine formulated with the oil-in-water adjuvant AS03. Vaccination commenced 2-3 weeks prior to the peak of pandemic activity. The vaccine was well tolerated and by using the HI assay, we showed that sero-protective responses (titres 40) were elicited in a majority of subjects (97%) by 2-3 weeks after vaccination. 4 Further studies have shown that influenza vaccines formulated with the oil-in-water adjuvant AS03 to be safe and highly efficacious in children, young adults and the elderly. 4, [12] [13] [14] [15] [16] [17] [18] [19] [20] In the current study, we characterized in detail the homologous and cross-reactive humoral and cellular response in HCW after AS03-adjuvanted A(H1N1)pdm09 vaccination. Our results show that vaccination induced serological (HI and SRH) and B cell (ASC and MBC) responses against A(H1N1)pdm09 and protoype seasonal H1N1 vaccine viruses that prevailed in the years preceding the pandemic. Furthermore, by IFN-g ELISPOT and intracellular cytokine staining assays, we demonstrate that both homologous and cross-reactive Th1 cytokine responses are elicited in HCWs after vaccination with the AS03-adjuvanted A (H1N1)pdm09 vaccine.
Results
In this study we have evaluated the early homologous and cross reactive immune responses to prototype H1N1 vaccine strains dating back to 1977 after a single low dose of pandemic influenza vaccine adjuvanted with the oil-in-water adjuvant AS03 in frontline HCWs. Blood samples were taken at 4 consecutive time points (day 0, 3, 7 and 14 post-vaccination) to evaluate the dynamics of the homologous and cross-reactive immune response to vaccination (Fig. 1) .
The cross-reactive haemagglutinin inhibition (HI) antibody response after pandemic vaccination Figure 2 shows the post-vaccination HI response against the homologous A/(H1N1)pdm09-like strain A/California/07/09 (California) and cross-reactivity against 6 seasonal influenza A H1N1 viruses. A sero-protective HI response was defined as an HI titer 40. 21 Prior to vaccination, 13.5% of the subjects had sero-protective HI titres against the homologous California strain with a geometric mean titer (GMT) of 8. Vaccination boosted the California-specific HI response where by day 7, a majority of subjects (78%, GMT D 156) were seroprotected. The HI response continued to increase up to days 14 and 21 postvaccination with 100% (GMT D 826) and 96% (GMT D 619) of the subjects, respectively having sero-protective HI titres 40.
The HI assay was used to examine the cross-reactive HI responses against 6 prototype H1N1 vaccine strains; A/USSR/ 90/77 (USSR) The cross-reactive single radial hemolysis (SRH) response to vaccination Figure 3 shows the pre-and post-vaccination SRH titres against the homologous California and cross-reactive responses against the New Caledonia and Texas strains. The European Agency for Evaluation of Medicinal Products criterion of protective serological response to influenza vaccines is a SRH titer of 25 mm 2 , which was used as a cut-off for serologic protection. Prior to vaccination, only 4% of the subjects had sero-protective SRH titer of 25 mm 2 against the Texas strain (GMT D 8), while 24% and 51% of subjects had sero-protective titres against California (GMT D 11) and New Caledonia (GMT D 16) strains, respectively. One week after vaccination, a majority of the subjects (76-84%) had sero-protective SRH titres against New Caledonia (GMT D 35) and California (GMT D 41) strains, while 28% had sero-protective SRH responses against the Texas strain (GMT D 15). The SRH response peaked 2 weeks after vaccination with 92-100% of the vaccinees having sero-protective responses against New Caledonia (GMT D 56) and California (GMT D 73) strains. Lower SRH responses were detected against the Texas strain with only 59% of subjects having sero-protective titres at 2 weeks post vaccination (GMT D 25).
B cellular responses after pandemic vaccination in health care workers
Antibody secreting cell response after vaccination The humoral response was further characterized by ASC response in peripheral blood mononuclear cells (PBMC) after vaccination. The peak virus-specific ASC response were observed at day 7 post-vaccination (Fig. 4) , while no ASC responses were observed before vaccination or at days 14 and 21 after vaccination (data not shown). IgG ASCs dominated the anti-California response (mean D 111 ASC per 1 £ 10 5 PBMC) and was significantly higher than the IgA (P < 0.001) and the IgM (P < 0.0001) ASC responses against the same strain (mean D 45 and 27 ASC per 1 £ 10 5 PBMC, respectively). Similarly, significantly higher (P < 0.0001) IgG ASCs were detected against Texas and New Caledonia strains (mean D 110 and 86 ASC per 1 £ 10 5 PBMC, respectively) compared with corresponding IgM responses against the same strains (mean D 28 and 23 ASC per 1 £ 10 5 PBMC, respectively). In general, weak IgM ASC responses were detected against all 3 H1N1 strains, which may suggest that relatively low ASC responses were elicited against novel epitopes.
The memory B cell response after vaccination Memory B cells (MBC) play a key role in anti-influenza immunity. Figure 5 shows that, prior to vaccination, IgG MBCs were detected against all the influenza A viruses tested with mean frequencies ranging between 114-263 cells per 1 £ 10 6 PBMC and no increase in the response was detected at 7 days after vaccination. The virus-specific IgG MBC frequencies peaked at 14 days after vaccination with the highest responses detected against the Brisbane and California strains (mean 470 and 410 cells per 1 £ 10 6 PBMC, respectively) and the lowest against the Brazil strain (mean 197 cells per 1 £ 10 6 PBMC). A significant increase (P < 0.05) in California-specific IgG MBC frequency was observed at day 14 (mean 410 cells per 1 £ 10 6 PBMC) compared to pre-vaccination (mean 200 cells per 1 £ 10 6 PBMC), while the responses against the other strains were not significantly different. Furthermore, we found a significant correlation between pre-vaccination MBC responses against California and the 6 seasonal H1N1 influenza strains with Spearman correlation coefficients (r) ranging between 0.6 and 0.96 ( Table 1) . A significant correlation was also observed between pre-vaccination MBC frequencies and day 7 HI responses against all viruses except the USSR and Brisbane strains ( Table 1) .
Interferon gamma response after vaccination Figure 6 shows the frequencies of PBMCs secreting IFN-g in an antigen-specific manner prior to vaccination (day 0) and at 7, 14 and 21 days post-vaccination.
Before vaccination, the highest response was observed against the Texas strain (mean number of IFN-g Before vaccination (day 0), significantly lower (P < 0.05) IFN-g responses were detected against California compared with the New Caledonia and Brisbane strains. At 21 days post-vaccination, significantly higher (P < 0.05) IFN-g levels were detected against all strains compared with pre-vaccination levels. Before vaccination, significantly lower (P < 0.05) frequencies of IL-2 and TNF-a were observed against Brisbane compared with the New Caledonia strain. Vaccination induced a significant increase (P < 0.05) in IL-2 response against all 3 strains compared with pre-vaccination levels. Increased TNF-a responses were also detected after vaccination with significantly higher (P < 0.05) frequencies detected against New Caledonia and Brisbane strains on day 21 compared with day 0. Figure 7B shows the frequency of Th1 cells simultaneously producing one or more cytokine (multi-functional T cells). After vaccination (day 21), significant increases (P < 0.05) in both triple and double cytokine producing cells were detected against all 3 strains compared with pre-vaccinaion levels (Fig. 7B) .
Discussion
The 1918 Influenza H1N1 pandemic killed up to 50 million people and H1N1 strains continued to circulate in the human (Fig. S1) . Despite the antigenic divergence, infection with the A(H1N1)pdm09 virus induced broad-cross reactive antibody responses against epitopes that are conserved on the HA of seasonal H1N1 and A(H1N1)pdm09 strains. 7, 10 Antibody responses directed at common HA epitopes may explain the broad cross-reactivity observed in our cohort following vaccination with the AS03-adjuvanted vaccine. The AS03 adjuvant itself may have contributed to the breath of the crossreactive response, however the underlying immunological mechanisms for this are not clear. A control group that received a nonadjuvanted A(H1N1)pdm09 vaccine would have shown the benefits of the AS03 adjuvant, however this was not possible as only the AS03 adjuvanted pandemic vaccine was licensed for use in Norway in 2009. We found that 13% of HCW had preexisting HI titres 40 to the California strain at baseline, which suggest exposure or subclinical infection with this virus. Almost all HCWs (97%) with preexisting sero-protective HI titres to A (H1N1)pdm09 were under the age of 60, therefore were not exposed to 1918-like H1N1 strains that have been shown to induced cross-reactive antibodies against the A(H1N1)pdm09 virus. 2 However, most of our study cohort (60%) had received the trivalent seasonal influenza vaccines in years preceding the 2009 pandemic 4 and this may have contributed to the preexisting immunity against both the A(H1N1)pdm09 virus and the seasonal H1N1 strains. 2 When stratified by age, older subjects (persons born before 1957) had similar HI and SRH GMTs against A(H1N1)pdm09 and seasonal H1N1 strains at baseline compared with the younger cohort (Fig. S2) . This differs from prior reports where higher frequencies of sero-protective antibodies and significantly lower infection rates have been observed in older adults over the age of 60 years. 2 Compared with the general public, the potential for exposure or asymptomatic subclinical infection is higher in HCWs and this may explain relatively high baseline sero-protective rates we observed in younger HCWs.
In this study, we evaluated the serological responses by 2 commonly used assays; HI and SRH with contrasting results. While both assays showed that vaccination induced complete protection against A(H1N1)pdm09 by day 14, contrasting results were observed against the Texas strain, with 100% and 59% seroprotection by HI and SRH assays, respectively. Generally there is a good correlation between HI and SRH responses against influenza A viruses 22 , therefore the discrepancy observed in our study is intriguing. Perhaps this may reflect different sensitivities of serological assays and measurement of different functionalities in the antibodies against different influenza strains, however further work is required to fully understand the measured differences.
The humoral immune response was further characterized by evaluating the influenza-specific ASC and MBC responses. The day 7 post-vaccination ASC response corresponds to the peak plasmablast CD19 C CD20 ¡ CD27 high CD38 high response 23 , and in our study, we observed a significant increase in IgG and IgA ASCs against the pandemic and seasonal H1N1 strains. The rapid ASC response one week after vaccination has been shown to be consistent with a recall response originating from activation of cross-reactive MBCs generated by previous influenza infections and/or vaccination. 6, 7, 24 An important finding in our study is that memory MBCs against A(H1N1)pdm09 strain were detected even before vaccination or widespread circulation of the pandemic virus, at frequencies similar to those observed against recently circulated seasonal H1N1 strains, suggesting cross reaction to conserved epitopes. Furthermore, we observed a significant positive correlation between the pre-vaccination MBC response against A(H1N1) pdm09 and that against the seasonal H1N1 strains ( Table 1) . A significant positive correlation was also observed between the pre-vaccination MBC responses and day 7 HI titres against most of the H1N1 strains tested. Collectively, our results strongly imply and support the suggestion that MBCs targeting A(H1N1)pdm09 exist in the human population and that they arise from prior exposure to seasonal H1N1 strains. 6 These A(H1N1)pdm09-specific MBCs have the capacity to rapidly differentiate into ASCs that secrete IgG antibodies after antigen re-encounter and have broad cross-reactivity. [25] [26] [27] The pre-existing MBCs targeting the A(H1N1)pdm09 virus may at least partly explain the fact that rapid sero-protective responses were elicited in a majority of subjects after only a single dose of the pandemic vaccine. 4 Further studies using chimeric virus constructs could evaluate the specificity of the post-vaccination antibody and MBC responses toward the globular head and the relatively well-conserved stalk domains of group 1 HA to confirm that the cross reactivity observed is due to conserved epitopes on the H1 haemagglutinin. 28 In this regard, immunization with chimeric virus constructs derived from novel influenza strains was shown to induce broadly cross-reactive HA stalk-specific antibody responses by ELISA and microneutralization assays. 29, 30 Cellular responses play a significant role in anti-influenza immunity (for a review see ref. 31 ). To assess the vaccine induced T-cell activity, we determined the influenza-specific IFN-g response by ELISPOT and IFN-g, IL-2 and TNF-a responses by ICS. Both ICS and ELISPOT analysis showed an increase in Th1 cytokine (IFN-g, IL-2 and TNF-a) responses against both the A(H1N1) pdm09 and seasonal H1N1 strains after vaccination. Both IFN-g and TNF-a have powerful anti-influenza virus activity and increased levels may help prevent severe influenza illness. [32] [33] [34] Furthermore, we observed an increase in homologous and cross-reactive Th1 CD4 T cells simultaneously secreting more than one cytokine (multifunctional T-cells), which are functionally superior to single cytokine producing cells eliciting anti-influenza immunity and conferring protection against lethal influenza infection. 35, 36 Furthermore, there was an increase in IFN-g C IL-2 C TNF-a C cells post-vaccination, which have a high proliferative potential and are an important target population for anti-A(H1N1)pdm-09 virus activity. 37 Interestingly, a very low A(H1N1)pdm09-specific IFN-g response was observed prior to vaccination by both the ELISPOT and ICS assays compared with responses against the seasonal strains. The higher baseline IFNg C cell frequencies observed against seasonal H1N1 viruses most likely reflects a recall memory T cell response to prior influenza vaccine and/or infection. In our study, the pandemic split virus antigen used for in vitro stimulation consists mainly of A(H1N1)pdm09 HA and NA, which shares only a few T-cell epitopes (12%) with HA and NA of seasonal H1N1 strains 10 , hence the pre-vaccination response against A(H1N1)pdm09 would mainly be na€ ıve T cells directed toward novel epitopes. Na€ ıve T cells require sustained antigen stimulation over days to produce IFN-g in vitro 38 , and this may explain the lack of a pre-vaccination IFN-g response after overnight stimulation in our ELISPOT and ICS assays.
In conclusion, we have shown that the AS03-adjuvanted A (H1N1)pdm09 vaccine induces both humoral and cellular crossreactive immune responses in HCW and this may have played a key role in eliciting rapid sero-protective immune responses, which contributed significantly to maintaining the integrity of the healthcare system during the pandemic. 4 Our results show that immune responses originally primed by exposure to seasonal strains can be recalled after pandemic vaccination and better understanding of mechanisms that result in cross-reactive immune responses may lead to the development of improved influenza vaccines.
Materials and Methods
Participants and study design In October 2009, 237 frontline healthcare workers at the Haukeland University Hospital, (Bergen, Norway) were vaccinated with a single dose of the AS03 adjuvanted monovalent split virus vaccine (Pandemrix, GlaxoSmithKline, www.clinicaltrials.gov, NCT01003288). 4 All participants provided written informed consent before being included in the study, which was approved by the Regional Ethical committee of Western Norway and the Norwegian Medicines Agency. The inclusion/exclusion criteria for this study are published elsewhere. 4 Consecutive blood samples were taken from the same subject at 4 time points (days 0, 7, 14 and 21 post-vaccination) for the serological (HI, SRH), ASC, memory B cell and IFN-g ELISPOT assays. For the intracellular cytokine staining (ICS) for Th1 cytokines, PBMCs were obtained from 8 subjects before vaccination and a separate cohort of 18 subjects on day 21 post-vaccination. On days 7 and 14, serological responses were determined in only 50 subjects as a part of a kinetic sub-study (Fig. 1) . Serum samples were aliquoted and stored at ¡70 C before use in the serological assays. PBMCs were isolated from a small group of HCWs (n D 39) using Cell preparation Tubes (CPT, BD Biosciences) according to manufacturer's instructions. Fresh lymphocytes were used in the antibody secreting cell ELISPOT assay and for intracellular cytokine staining of CD4 C T-cells. Remaining lymphocytes were frozen at ¡70 C and prioritized for use in the memory B cell ELISPOT followed by the IFN-g ELISPOT assays. (Fig. S1 ). Assays were performed in duplicate and the geometric mean titer (GMT) was calculated. The pre-and post-vaccination, influenza-specific HI antibody response was determined by the HI assay using 8 HA units of each virus strain and 0.7% turkey red blood cells, as described earlier. 4 HI titers were defined as the reciprocal of the dilution exceeding 50% haemagglutination. Negative titers were assigned a value of 5 for calculation purposes.
Antibody assays
The single radial hemolysis (SRH) responses against A/Texas/ 36/91, A/New Caledonia/20/99 and A/California/07/09 strains were conducted at the University of Siena, Italy, as previously described.
39-41
B cell assays The virus-specific IgG, IgA and IgM antibody secreting cell (ASC) response against A/California/07/09, A/Texas/36/91 and A/New Caledonia/20/99 split virus antigens was determined pre and post-vaccination by ELISPOT assay using fresh PBMCs as described earlier. 23 The numbers of IgG, IgA and IgM ASCs were evaluated at 7 days post-vaccination, as this has previously been shown to be the peak response after inactivated influenza vaccination. 23 The virus-specific IgG memory B cell (MBC) response against A/California/07/09, A/Brisbane/59/07, A/Texas/36/91 and A/ New Caledonia/20/99 split virus antigens and A/USSR/90/77, A/Brazil/11/1978, A/Taiwan/1/86 whole virus was quantified by ELISPOT as described earlier. 42 Results are presented as virusspecific IgG MBC cells per 1 £ 10 6 PBMCs.
Interferon gamma ELISPOT assay
The influenza-specific IFN-g response pre and post-vaccination was examined by using 96 well plates pre-coated with anti-IFN-g antibodies according to the manufacturer s instructions (Mabtech AB, Sweden). PBMCs (4 £ 10 5 cells per well) were added in RPMI-1640 medium supplemented with 10% fetal calf serum with negative control (medium alone) and the split virus influenza H1N1 antigens from; A/New Caledonia/20/99, A/Texas/36/91, A/Brisbane/59/07 and A/California/7/09 (X179a). Plates were incubated overnight (37 C, 5% CO 2 ) and developed the following day. The plates were read using an Immunoscan TM reader and associated software (CTL-Europe). The negative control was subtracted from the influenza-specific response.
Intracellular cytokine staining (ICS) for multi-functional CD4
C T cell responses PBMCs from vaccinated subjects were stimulated overnight with A/California/7/09 (X179a), A/New Caledonia/20/99 and A/Brisbane/59/07 split virus antigens and the cells were stained for intracellular Th1 cytokines IFN-g, IL-2 and TNF-a and the percentage of single, or multiple cytokine producing CD4
C Tcells were analyzed by flow cytometry as described earlier. 43 
Statistical assays
Differences in the IFN-g, ASC and MBC ELISPOT responses were analyzed by non-parametric Kruskal-Wallis test. Correlations between pre-vaccination MBC responses against the A(H1N1)pdm09 virus and seasonal influenza strains were determined by Spearman correlation coefficient analysis. The KruskalWallis and Spearman correlation analysis were performed by GraphPad Prism version 6.00 for Mac (GraphPad software, La Jolla, CA, USA). Differences between intracellular cytokine responses at days 0 and 21 were determined by the student t test and a partial permutation test by using SPICE version 5.1 software, as described earlier.
44 P < 0.05 was considered as significant for all statistical tests.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
The split virus influenza antigens were kindly provided by Glaxo Smithkline (Belgium). We thank all the healthcare workers that volunteered for the clinical trial, the clinical staff at the Bergen Clinical Vaccine consortium and staff at the Influenza Center who processed samples. 
Supplemental Material
Supplemental data for this article can be accessed on the publisher's website.
